Dupixent (dupilumab), a monoclonal antibody approved to treat asthma, atopic dermatitis and three other inflammatory diseases, has now been shown to be effective in chronic obstructive pulmonary disease (COPD), the third leading cause of death in the world. Results of a Phase 3 trial of the drug showed that it achieved a 30% reduction in moderate or severe acute exacerbations in COPD, Sanofi SA announced on 23 March. Dupixent is being jointly developed by Sanofi and Regeneron Pharmaceuticals Inc.
